

In re: Anagnostou et al.
Serial No.: To be Assigned
Filed: Concurrently Herewith
Page 3 of 3

A2
canceled.

28. A method according to claim 23, wherein said endothelial injury is caused by cancer.

29. A method according to claim 23, wherein said erythropoietin is administered intravenously.


REMARKS

This application is a divisional of the parent application, and claims previously cancelled in response to the restriction requirement are submitted herewith.

The additional claims submitted above are added to complete the record, and are supported by the specification (*see, e.g.*, page 12, lines 31-32).

It is submitted that this application is in condition for substantive examination, which action is respectfully requested.


Respectfully submitted,


Kenneth D. Sibley
Registration No. 31,665

Correspondence Address
USPTO Customer No.: 20792
Myers Bigel Sibley & Sajovec
P.O. Box 37428
Raleigh, North Carolina 27627
Telephone: 919-854-1400
Facsimile (919) 854-1401

"Express Mail" mailing label number EL533609420US
Date of Deposit: March 15, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner of Patents, Washington, DC 20231.


Kenneth D. Sibley
Date of Signature: March 15, 2000